论文部分内容阅读
国家“九五”重点科技攻关课题“血脂康调整血脂对冠心病二级预防的研究”已经通过了卫生部验收。该课题系国际首次对东方人群进行的有关药物调整血脂对冠心病二级预防的大规模临床研究。为进一步了解“九五”课题对我围冠心病预防的意义,日前本刊对该课题组负责人、中国医学科学院阜外心血管病医院陆宗良教授进行了专访。
National “Ninth Five-Year” key scientific and technological topics “Xuezhikang blood lipid-lowering prevention of coronary heart disease secondary research” has passed the Ministry of Health acceptance. This issue is the first international large-scale clinical study on the secondary prevention of coronary heart disease with lipid-lowering drugs on Oriental population. In order to further understand the significance of the Ninth Five-Year Plan on the prevention of coronary heart disease in our hospital, an interview was held with Prof. Lu Zongliang, the head of the research group and the Fuwai Hospital of Cardiovascular Diseases of the Chinese Academy of Medical Sciences.